COMy 2022 | Modakafusp alfa combinations for treating multiple myeloma in the near future
Modakafusp alfa (previously known as TAK-573) has shown promise for heavily pre-treated patients with relapsed/refractory (R/R) multiple myeloma (MM) in the first-in-human Phase I study (NCT03215030) presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, Atlanta, GA. In this video, Dan Vogl, MD, MSCE, University of Pennsylvania, Philadelphia, PA, discusses where modakafusp alfa can fit in the future treatment landscape, particularly in combination with proteasome inhibitors, IMiDs and anti-CD38 antibodies in the early setting. Dr Vogl also explores its potential to augment other immunotherapies such as CAR-T cell therapy. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Consulting fees and research funding from Takeda. Consulting fees from Karyopharm, Janssen, GSK, Sanofi, Oncopeptides, and CSL Behring. Research funding from Active Biotech.
